预约演示
更新于：2026-08-26
Colchicine
秋水仙碱
更新于：2026-08-26
概要
基本信息
简介武田制药公司于 1995 年 1 月批准秋水仙碱标志着医学界的一个重要里程碑。这种小分子药物属于受人尊敬的微管蛋白聚合抑制剂类，可阻碍细胞中微管的形成。这种治疗机制已被证明对治疗一系列疾病特别有益，包括痛风、家族性地中海热和心包炎。通过阻碍嗜中性粒细胞（在这些情况下是炎症的核心细胞）的运动，秋水仙碱可有效减轻受影响关节和其他组织的疼痛和肿胀。尽管有其优点，但秋水仙碱有一些潜在的副作用，例如胃肠道不适和肌肉无力，这些副作用在较高剂量时可能更为明显。尽管如此，秋水仙碱仍然是治疗各种炎症的重要药物。 |
药物类型 小分子化药 |
别名 Colchicine、Colchicine (JP17/USP)、colchicine USP + [10] |
靶点 |
作用方式 抑制剂 |
作用机制 微管蛋白抑制剂 |
最高研发阶段批准上市 |
首次获批日期 中国 (1995-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C22H25NO6 |
InChIKeyIAKHMKGGTNLKSZ-INIZCTEOSA-N |
CAS号64-86-8 |
关联
456
项与 秋水仙碱 相关的临床试验NCT07569328
Low-dose Colchicine for CABG Graft Failure Prevention: A Randomized, Double-Blind, Placebo-Controlled Trial
CTIS2026-526460-20-00
A RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL OF COLCHICINE IN AMYOTROPHIC LATERAL SCLEROSIS (CO-ALS II)
CTRI/2025/11/097560
COLchicine in HEart Failure (COLHEF): A Randomized Controlled Study - NIL
100 项与 秋水仙碱 相关的临床结果
登录后查看更多信息
100 项与 秋水仙碱 相关的转化医学
登录后查看更多信息
100 项与 秋水仙碱 相关的专利（医药）
登录后查看更多信息
19,774
项与 秋水仙碱 相关的文献（医药）2026-12-01Molecular & general genetics : MGG
Creation of new varieties of tetraploid willow (Salix suchowensis) and their evaluation for salt tolerance
Article
作者: Liu, Guoyuan ; Chen, Yanhong ; Kan, Siwei ; Wei, Hui ; Li, Mengru ; Mei, Yandong ; Deng, Mingchao ; Qian, Chaonan ; Zhang, Jian
To break the germplasm bottleneck that constrains afforestation in coastal and inland saline alkali soils, this study focused on Salix spp., a fast growing, ecological tree genus, and aimed to establish a highly efficient, low chimera protocol for tetraploid willow induction through refined colchicine treatment. The overarching objective was to expand forest genetic diversity and provide both theoretical insights and elite plant materials for the development of salt-tolerant willow cultivars. The colchicine-based chromosome doubling procedure was systematically optimized; 0.1% (w/v) colchicine for 12 h was identified as the optimal condition, and ploidy levels were verified by flow cytometry. Compared with the diploid controls, the induced tetraploids exhibited pronounced gigas characteristics: leaf length and width increased by 1.6- and 1.4-fold, respectively, and leaf fresh weight was 2.4-fold higher. After 14 d of 50 mmol/L NaCl treatment, tetraploids contained only 50% of the K⁺ level observed in diploids, resulting in a significantly higher K⁺/Na⁺ ratio. POD activity in tetraploids was approximately twice that of diploids, and total chlorophyll content was likewise 1.2-fold higher, collectively demonstrating superior growth performance and physiological homeostasis under saline conditions. These results demonstrate that the optimized chromosome doubling protocol markedly improves tetraploid induction efficiency and effectively enhances the salt tolerance of S. suchowensis. Future research will integrate whole genome re-sequencing to dissect dosage effects and identify key genomic loci governing salt tolerance, establish a marker assisted selection framework for accelerated tetraploid breeding, and conduct multi-site field trials to comprehensively evaluate stability and ecological adaptability. Such efforts are expected to expedite the commercial deployment of high salt tolerant willow cultivars in coastal shelter belt construction and large-scale saline alkali land restoration.
2026-11-01AMERICAN HEART JOURNAL
Interpreting apparent differences among the major colchicine trials for cardiovascular prevention: A descriptive compatibility analysis
Article
作者: Eikelboom, John ; Yi, Qilong ; Gerstein, Hertzel C ; Mosterd, Arend ; Scheier, Thomas C
BACKGROUND:
Recent analyses and commentaries on the major colchicine trials have treated COLCOT and LoDoCo2 as defining the expected benefit of colchicine for cardiovascular prevention, with CLEAR SYNERGY viewed as the discordant or outlying study because of its neutral result. We performed a descriptive analysis to examine how the trial that is least readily reconciled with an assumed true treatment effect changes depending on different assumed effects.
METHODS:
We used the published hazard ratios (HRs) and 95% confidence intervals from COLCOT, LoDoCo2, and CLEAR SYNERGY. For each assumed true treatment effect, we calculated the probability that a hypothetical repeat of each trial, with the same standard error as that study and centered on the assumed treatment effect, would yield a 95% confidence interval containing the estimate observed in that trial. The main analysis used the published primary composite outcome from each trial and additional exploratory analyses separately examined cardiovascular death, myocardial infarction, and stroke.
RESULTS:
For the primary composite outcomes, the observed HRs were 0.77 for COLCOT, 0.69 for LoDoCo2, and 0.99 for CLEAR SYNERGY. Across assumed HRs from 0.65 to 1.00, the trial least readily reconciled changed from CLEAR SYNERGY under larger assumed benefits to LoDoCo2 under smaller assumed benefits. Exploratory component analyses showed different patterns by outcome: cardiovascular death estimates were relatively similar across the 3 trials (HRs 0.84, 0.80, and 1.03); myocardial infarction estimates were broadly comparable in COLCOT and CLEAR SYNERGY but more favourable in LoDoCo2 (HRs 0.91, 0.88, and 0.70); and stroke estimates were divergent across all 3 trials (HRs 0.26, 0.66, and 1.15).
CONCLUSIONS:
When outlier status is assigned based only on observed trial results, the trial least readily reconciled with the evidence depends on the assumed true treatment effect. Although differences in design, conduct, population, or inflammatory context may explain the apparently divergent results of the 3 large colchicine trials, CLEAR SYNERGY cannot be designated the outlier on the basis of its neutral result.
2026-10-01American journal of preventive cardiology
The effect of colchicine on pericoronary adipose tissue attenuation by serial coronary CT angiography: A substudy of the Ekstrom trial
Article
作者: Kinninger, A ; Budoff, M ; Irannejad, K ; Verghese, D ; Garikapati, V ; Colasurdo, J R ; Bhandari, M ; Iskander, B ; Mora, R ; Roy, S ; Punnanithinont, N ; Lakshmanan, S
Introduction:
Inflammation plays a pivotal role in initiation and progression of coronary artery disease (CAD). Pericoronary adipose tissue (PCAT) attenuation on coronary CT angiography (CCTA) is a novel non-invasive biomarker of coronary inflammation. Low dose colchicine has been shown to safely lower cardiovascular events among patients with stable CAD. We sought to investigate whether colchicine is associated with changes in PCAT by serial CCTA in patients enrolled in the Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients with STable CoROnary Artery Disease CoMpared to Placebo (EKSTROM) trial.
Methods:
This is a post-hoc analysis of the EKSTROM trial, a prospective, placebo-controlled serial CCTA trial that randomized patients with stable CAD to receive either colchicine (0.5 mg/day) or placebo, and followed for 12 months. PCAT attenuation was quantified using partially-automated Medis QAngioCT software. Multivariable linear regression models were adjusted for traditional cardiovascular risk factors and baseline PCAT attenuation to examine the change in mean PCAT attenuation between the treatment groups.
Results:
The analysis included 71 participants (12% female, mean age 64.6 ± 7.3, mean hsCRP 0.8 mg/L). Mean PCAT attenuation in the colchicine group was -73.6 HU ±8.0 at baseline which increased to -73.1 HU ±8.2 at 12-month follow-up. Mean PCAT attenuation in the placebo group was -75.3 HU ±7.4 at baseline, which increased to 74.5 HU ±6.8 at follow-up, with a between group change of 0.3 HU ±8.0 (p = 0.857). Multivariate regression analysis showed no significant change in mean PCAT attenuation between groups.
Conclusion:
Colchicine was not associated with a significant change in PCAT over 12 months in participants in the EKSTROM trial with stable CAD. Larger studies with long-term follow up are needed to evaluate the mechanistic benefits of colchicine on the complex interactions of coronary atherosclerosis, inflammation, and adverse CV risk.
100 项与 秋水仙碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性痛风 | 澳大利亚 | 2026-06-04 | |
| 动脉粥样硬化 | 美国 | 2023-06-16 | |
| 冠心病 | 加拿大 | 2021-08-23 | |
| 家族性地中海热 | 美国 | 2009-07-29 | |
| 痛风 | 中国 | - | 1995-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心肌炎 | 临床3期 | 法国 | 2024-07-16 | |
| 心房颤动 | 临床3期 | - | 2017-12-02 | |
| 急性心肌梗塞 | 临床2期 | 法国 | 2018-07-23 | |
| 高尿酸血症 | 临床2期 | 美国 | 2014-05-01 | |
| 心脏衰竭 | 临床前 | 中国 | 2025-07-12 | |
| 血管钙化 | 临床前 | 中国 | 2025-06-14 | |
| 心包炎 | 临床前 | 美国 | 2024-10-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 2,920 | 窪廠夢簾蓋鹹網鏇構蓋(艱願獵膚醖廠窪鹽構淵) = 憲構壓簾醖鹹蓋糧網網 顧鑰膚艱顧憲衊醖窪繭 (鏇窪獵簾製築範願構獵, 12.8) 更多 | 积极 | 2026-07-06 | ||
N/A | 150 | Corticosteroids | 顧艱選窪醖鑰鬱廠繭願(構醖鏇築襯廠憲遞獵遞) = 廠蓋衊遞網蓋鏇鹹範積 膚簾廠選襯鏇獵餘繭遞 (鏇憲夢鹹窪蓋糧艱範製 ) 更多 | 不佳 | 2026-06-11 | ||
Anti-IL-1 therapy | 築憲憲鹹衊齋鏇獵鏇齋(淵鹽醖窪壓廠襯鑰窪鏇) = 鏇鬱衊壓鑰醖獵憲繭鏇 製淵艱鑰鹹淵糧窪鹹鏇 (願襯鹽衊顧選蓋淵願鬱 ) | ||||||
N/A | 25 | pathway-aligned targeted therapy | 觸窪遞鑰觸襯餘蓋餘窪(鹽獵網顧蓋壓窪繭製築) = 築鬱獵憲積遞夢憲齋憲 鏇網製膚窪觸遞廠鬱齋 (積壓襯糧膚選鹹窪襯鏇 ) 更多 | 积极 | 2026-06-11 | ||
N/A | 148 | 築淵窪鬱顧鏇築觸蓋選(範醖鹹獵艱構鹽網壓築) = 鬱鹹餘廠築積窪蓋積膚 鹹襯繭淵構餘顧築壓築 (鹹窪鏇觸遞廠範築鬱鑰 ) 更多 | 积极 | 2026-04-16 | |||
临床4期 | 204 | 築觸築廠鬱壓積鹽餘夢(艱獵選選獵襯繭選齋糧) = 壓鬱顧壓範繭糧製獵壓 積選積鹹鏇鏇壓憲構醖 (遞膚觸鑰襯鹹夢鹹築廠 ) 更多 | 积极 | 2026-02-01 | |||
N/A | 208 | - | 积极 | 2025-10-24 | |||
Glucocorticoids | 膚廠鹹鹽壓衊壓糧網鑰(鏇願廠壓鹽膚築製鑰蓋) = 窪願簾遞齋憲鑰蓋鬱廠 膚顧衊壓鏇製襯鬱觸獵 (窪網製鹹醖蓋艱構艱壓 ) | ||||||
临床3期 | - | 252 | 築構鹹糧繭淵選構糧築(顧簾壓憲齋選衊顧膚簾) = 網築窪築獵鑰簾顧廠窪 鑰願糧憲鏇壓選衊獵淵 (憲窪鬱積餘鹽積膚觸鬱 ) | 积极 | 2025-10-01 | ||
临床2期 | 120 | 壓窪蓋顧選鹽憲衊糧鹹(膚積齋憲構鏇鹹願夢餘): RD = -15.0 (95.0% CI, -28.3 ~ -1.7), P-Value = 0.031 更多 | 积极 | 2025-07-15 | |||
Placebo | |||||||
临床3期 | 3,209 | 網製齋糧窪願夢鹹製鏇(顧淵觸膚鬱願鏇願簾觸) = 廠鏇憲範鹽憲積網鏇鬱 鏇醖艱構淵觸製衊鹽構 (鏇醖齋糧淵繭蓋構願積 ) 更多 | 积极 | 2025-07-01 | |||
Placebo | 網製齋糧窪願夢鹹製鏇(顧淵觸膚鬱願鏇願簾觸) = 製餘夢鹽蓋醖壓糧餘選 鏇醖艱構淵觸製衊鹽構 (鏇醖齋糧淵繭蓋構願積 ) 更多 | ||||||
临床3期 | 7,567 | 鹹蓋築願蓋範艱鬱繭廠(觸選夢簾繭鏇淵醖壓齋) = 窪糧簾簾願憲顧夢餘鬱 繭選鹽願網廠範襯鑰廠 (網網憲築觸願範構淵遞 ) 更多 | 不佳 | 2025-06-01 | |||
Placebo | 鹹蓋築願蓋範艱鬱繭廠(觸選夢簾繭鏇淵醖壓齋) = 觸鏇夢製糧選餘繭襯選 繭選鹽願網廠範襯鑰廠 (網網憲築觸願範構淵遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用